$TNON
Tenon Medical, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024068416 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $887.0K $901.0K $743.0K
YoY Change -6.04% 21.27% 450.37%
Cost Of Revenue $469.0K $431.0K $549.0K
YoY Change 14.67% -21.49% 102.58%
Gross Profit $418.0K $470.0K $194.0K
YoY Change -21.87% 142.27% -242.65%
Gross Profit Margin 47.13% 52.16% 26.11%
Selling, General & Admin $2.976M $3.634M $3.615M
YoY Change -6.3% 0.53% -22.47%
% of Gross Profit 711.96% 773.19% 1863.4%
Research & Development $657.0K $708.0K $901.0K
YoY Change -10.85% -21.42% 37.14%
% of Gross Profit 157.18% 150.64% 464.43%
Depreciation & Amortization $105.0K $86.00K $35.00K
YoY Change 128.26% 145.71% 84.21%
% of Gross Profit 25.12% 18.3% 18.04%
Operating Expenses $3.633M $4.342M $4.516M
YoY Change -7.16% -3.85% -15.11%
Operating Profit -$3.215M -$3.872M -$4.322M
YoY Change -4.83% -10.41% -20.78%
Interest Expense $31.00K $39.00K
YoY Change 675.0%
% of Operating Profit
Other Income/Expense, Net $31.00K $46.00K $37.00K
YoY Change -32.61% 24.32% -215.63%
Pretax Income -$3.184M -$3.826M -$4.285M
YoY Change -4.44% -10.71% -21.92%
Income Tax
% Of Pretax Income
Net Earnings -$3.184M -$3.826M -$4.285M
YoY Change -4.44% -10.71% -21.92%
Net Earnings / Revenue -358.96% -424.64% -576.72%
Basic Earnings Per Share -$3.63 -$1.02 -$0.33
Diluted Earnings Per Share -$3.63 -$1.02 -$0.33
COMMON SHARES
Basic Shares Outstanding 3.952M shares 3.729M shares 11.25M
Diluted Shares Outstanding 877.0 shares 3.749K shares 13.05K shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.162M $1.968M $6.345M
YoY Change 171.79% -68.98% -60.38%
Cash & Equivalents $9.162M $1.968M $5.852M
Short-Term Investments $493.0K
Other Short-Term Assets $543.0K $831.0K $413.0K
YoY Change 57.39% 101.21% 197.12%
Inventory $607.0K $609.0K $570.0K
Prepaid Expenses $413.0K
Receivables $876.0K $679.0K $601.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.19M $4.087M $7.929M
YoY Change 125.43% -48.46% -52.97%
LONG-TERM ASSETS
Property, Plant & Equipment $906.0K $904.0K $945.0K
YoY Change -5.23% -4.34% 292.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M
YoY Change
Other Assets $482.0K $490.0K $219.0K
YoY Change -30.65% 123.74% 329.41%
Total Long-Term Assets $1.851M $1.919M $1.926M
YoY Change -21.4% -0.36% 51.3%
TOTAL ASSETS
Total Short-Term Assets $11.19M $4.087M $7.929M
Total Long-Term Assets $1.851M $1.919M $1.926M
Total Assets $13.04M $6.006M $9.855M
YoY Change 78.18% -39.06% -45.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.093M $1.111M $912.0K
YoY Change 43.25% 21.82% 164.35%
Accrued Expenses $908.0K $932.0K $1.130M
YoY Change 59.02% -17.52% -31.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.178M $3.403M $6.866M
YoY Change 3.01% -50.44% 207.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.670M $1.771M $2.086M
YoY Change -2.68% -15.1% 166.75%
Total Long-Term Liabilities $1.670M $1.771M $2.086M
YoY Change -2.68% -15.1% 166.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.178M $3.403M $6.866M
Total Long-Term Liabilities $1.670M $1.771M $2.086M
Total Liabilities $4.848M $5.174M $8.952M
YoY Change 0.98% -42.2% 196.62%
SHAREHOLDERS EQUITY
Retained Earnings -$65.66M -$62.48M -$48.61M
YoY Change 26.42% 28.53% 71.06%
Common Stock $3.000K $4.000K $22.00K
YoY Change 50.0% -81.82% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.191M $832.0K $903.0K
YoY Change
Total Liabilities & Shareholders Equity $13.04M $6.006M $9.855M
YoY Change 78.18% -39.06% -45.65%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.184M -$3.826M -$4.285M
YoY Change -4.44% -10.71% -21.92%
Depreciation, Depletion And Amortization $105.0K $86.00K $35.00K
YoY Change 128.26% 145.71% 84.21%
Cash From Operating Activities -$2.343M -$2.420M -$3.176M
YoY Change -25.74% -23.8% 14.95%
INVESTING ACTIVITIES
Capital Expenditures $104.0K $0.00 $128.0K
YoY Change 76.27% -100.0% -412.2%
Acquisitions
YoY Change
Other Investing Activities $1.257M
YoY Change -115.44%
Cash From Investing Activities -$104.0K $0.00 $1.129M
YoY Change -123.96% -100.0% -113.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.641M 0.000 4.707M
YoY Change 3593.87% -100.0% -66.84%
NET CHANGE
Cash From Operating Activities -2.343M -2.420M -3.176M
Cash From Investing Activities -104.0K 0.000 1.129M
Cash From Financing Activities 9.641M 0.000 4.707M
Net Change In Cash 7.194M -2.420M 2.660M
YoY Change -392.44% -190.98% -18.1%
FREE CASH FLOW
Cash From Operating Activities -$2.343M -$2.420M -$3.176M
Capital Expenditures $104.0K $0.00 $128.0K
Free Cash Flow -$2.447M -$2.420M -$3.304M
YoY Change -23.86% -26.76% 21.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41364
dei Entity Registrant Name
EntityRegistrantName
TENON MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5574718
dei Entity Address Address Line1
EntityAddressAddressLine1
104 Cooper Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Gatos
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95032
dei City Area Code
CityAreaCode
(408)
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TNON
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3951767 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1968000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2428000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
679000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
518000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
609000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
554000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
831000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
4087000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3889000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
904000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
961000 usd
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
525000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646000 usd
CY2024Q2 us-gaap Deferred Costs
DeferredCosts
439000 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
798000 usd
CY2024Q2 us-gaap Assets
Assets
6006000 usd
CY2023Q4 us-gaap Assets
Assets
6345000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1111000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
433000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
932000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
808000 usd
CY2024Q2 tnon Accrued Commissions Current
AccruedCommissionsCurrent
1089000 usd
CY2023Q4 tnon Accrued Commissions Current
AccruedCommissionsCurrent
470000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
271000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
77000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1173000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3403000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3140000 usd
CY2024Q2 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1481000 usd
CY2023Q4 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1999000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
290000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
428000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
5174000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5567000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3780827 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3780827 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2600311 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2600311 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60003000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55894000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62475000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55073000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-46000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
832000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
778000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6006000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6345000 usd
CY2024Q2 us-gaap Revenues
Revenues
901000 usd
CY2023Q2 us-gaap Revenues
Revenues
743000 usd
us-gaap Revenues
Revenues
1620000 usd
us-gaap Revenues
Revenues
1176000 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
431000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
549000 usd
us-gaap Cost Of Revenue
CostOfRevenue
680000 usd
us-gaap Cost Of Revenue
CostOfRevenue
1029000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
470000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
194000 usd
us-gaap Gross Profit
GrossProfit
940000 usd
us-gaap Gross Profit
GrossProfit
147000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
708000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
901000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1377000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1735000 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1448000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1883000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2829000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3909000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2186000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1732000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4112000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3711000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
4342000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4516000 usd
us-gaap Operating Expenses
OperatingExpenses
8318000 usd
us-gaap Operating Expenses
OperatingExpenses
9355000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3872000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4322000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7378000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9208000 usd
CY2024Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
39000 usd
CY2023Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
37000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
66000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
93000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
34000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
93000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3826000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4285000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7402000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9115000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.5
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3749 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1305 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3301 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1215 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3826000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4285000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7402000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9115000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3826000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4269000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7356000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9087000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3624000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1034000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3826000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
832000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2474000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1054000 usd
CY2023Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1644000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4285000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
903000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
778000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2052000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1804000 usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
-3554000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
46000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7402000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
832000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6252000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2094000 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1644000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9115000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
903000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7402000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9115000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2052000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2094000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
189000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
46000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
111000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
207000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
373000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
155000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
442000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
325000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
678000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
362000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
385000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
698000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-123000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-109000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4758000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6752000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
6503000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
493000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5798000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2437000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1934000 usd
tnon Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
-4808000 usd
tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
143000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4371000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4665000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-460000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3723000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2428000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2129000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1968000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5852000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1186000 usd
tnon Reclassification Of Deferred Offering Costs To Additional Paidin Capital
ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital
130000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Organization and Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nature of operations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System (“the Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principles of consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements of the Company for the three and six months ended June 30, 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. In 2024, TTAG was dissolved and, as such, the financial statements for the three and six months ended June 30, 2024 and as of June 30, 2024 only include the accounts of the Company.</p>
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation.</p>
tnon Percentage Of Valuation Allowance In Deferred Tax Assets
PercentageOfValuationAllowanceInDeferredTaxAssets
1 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5222337 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2199690 shares
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1350000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1234000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
446000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
273000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
904000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
961000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
86000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
35000 usd
us-gaap Depreciation
Depreciation
173000 usd
us-gaap Depreciation
Depreciation
60000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
531000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
334000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
401000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
474000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
932000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
808000 usd
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2026Y
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
73000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
73000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
146000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
146000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
525000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
271000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
290000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
428000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
561000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
684000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
154000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
310000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
144000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
608000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
561000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
148000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
144000 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P2Y
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5500000 usd
CY2023Q2 tnon Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.03 pure
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
tnon Purchase Exceed Amount
PurchaseExceedAmount
500000000 usd
us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
100000 shares
tnon Percentage Of Outstanding Shares
PercentageOfOutstandingShares
0.0499 pure
tnon Percentage Of Shares Issued To Stockholders
PercentageOfSharesIssuedToStockholders
0.50 pure
tnon Deemed Liquidation Percentage
DeemedLiquidationPercentage
1.10 pure
tnon Increased Percentage Of Deemed Liquidation
IncreasedPercentageOfDeemedLiquidation
0.10 pure
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
83391 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1034 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1054 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2052 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2094 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2000000 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y
CY2023Q2 tnon Class Of Warrants Of Rights Grant Date Fair Value Of Warrants
ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants
3164
CY2023Q2 tnon Fair Value Of Offering Warrant
FairValueOfOfferingWarrant
1.58
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3
CY2023Q2 tnon Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate
0.0518 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1 pure
CY2023Q2 tnon Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation
0.063 pure
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
2377 usd
us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
252 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
185 usd
CY2024Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
2310 usd
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
dei Local Phone Number
LocalPhoneNumber
649-5760
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.50
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1215 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1305 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3301 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3749 shares
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
tnon Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
usd
tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
usd
tnon Reclassification Of Deferred Offering Costs To Additional Paidin Capital
ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001560293

Files In Submission

Name View Source Status
0001213900-24-068416-index-headers.html Edgar Link pending
0001213900-24-068416-index.html Edgar Link pending
0001213900-24-068416.txt Edgar Link pending
0001213900-24-068416-xbrl.zip Edgar Link pending
ea0210949-10q_tenon.htm Edgar Link pending
ea021094901ex31-1_tenon.htm Edgar Link pending
ea021094901ex31-2_tenon.htm Edgar Link pending
ea021094901ex32-1_tenon.htm Edgar Link pending
ea021094901ex32-2_tenon.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
ea0210949-10q_tenon_htm.xml Edgar Link completed
Show.js Edgar Link pending
tnon-20240630.xsd Edgar Link pending
tnon-20240630_def.xml Edgar Link unprocessable
tnon-20240630_lab.xml Edgar Link unprocessable
tnon-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
tnon-20240630_cal.xml Edgar Link unprocessable